-+ 0.00%
-+ 0.00%
-+ 0.00%

Ligand partner Travere wins full FDA approval for FILSPARI in FSGS

PUBT·04/14/2026 11:05:38
Listen to the news
Ligand partner Travere wins full FDA approval for FILSPARI in FSGS
  • Travere Therapeutics secured full FDA clearance for FILSPARI (sparsentan) to reduce proteinuria in focal segmental glomerulosclerosis patients ages 8 and older without nephrotic syndrome.
  • Ligand Pharmaceuticals will receive a 9% royalty on worldwide net sales of FILSPARI.
  • Approval expands FILSPARI beyond IgA nephropathy into a second rare kidney disease indication.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ligand Pharmaceuticals Inc. published the original content used to generate this news brief on April 14, 2026, and is solely responsible for the information contained therein.